Dr. Richard Nguyen is the manager, alliance management PICI for the collaboration between Weill Cornell Medicine and the Parker Institute of Cancer Immunotherapy (PICI). In this role, he supports the Center for Technology Licensing (CTL) and Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center, by serving as the primary liaison to manage intellectual property matters pertaining to the consortium.
Dr. Nguyen leverages over a decade of experience in securing and managing strategic partnerships with academic collaborators and top pharmaceutical and biotechnology companies. Prior to joining Weill Cornell Medicine in 2024, Dr. Nguyen led business development efforts at Xylyx Bio, Inc., a university spinout that develops advanced preclinical drug testing platforms for metastatic cancer and fibrotic diseases. During the pandemic, he worked with a multidisciplinary team of experts on the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative to evaluate SARS-CoV-2 point-of-care diagnostics for feasibility of accelerated scale-up manufacturing. He has developed an expansive network from working at top-tier research institutions and in various technology transfer offices including as a technology licensing officer at Columbia Technology Ventures. He has also participated in several accelerator and entrepreneurial programs, contributing his expertise toward evaluating innovations for commercial potential and developing business strategies for early-stage ventures.
Dr. Nguyen earned his Ph.D. in Biomedical Engineering from the University of North Carolina at Chapel Hill with a minor in Neurobiology. He holds a B.S. in Biomedical Engineering from the University of North Carolina at Chapel Hill with minors in Physics and French.
